HomeFed (OTCMKTS:HOFD) Stock Price Passes Below 50-Day Moving Average of $37.47

Share on StockTwits

HomeFed Co. (OTCMKTS:HOFD) passed below its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $37.47 and traded as low as $37.40. HomeFed shares last traded at $37.53, with a volume of 6,524 shares.

The company has a debt-to-equity ratio of 0.23, a quick ratio of 2.31 and a current ratio of 2.31.

COPYRIGHT VIOLATION NOTICE: “HomeFed (OTCMKTS:HOFD) Stock Price Passes Below 50-Day Moving Average of $37.47” was originally posted by Ticker Report and is the property of of Ticker Report. If you are reading this article on another website, it was stolen and republished in violation of U.S. and international copyright & trademark law. The legal version of this article can be viewed at https://www.tickerreport.com/banking-finance/4380228/homefed-otcmktshofd-stock-price-passes-below-50-day-moving-average-of-37-47.html.

About HomeFed (OTCMKTS:HOFD)

HomeFed Corporation, together with its subsidiaries, invests in and develops residential and commercial real estate properties in California, Virginia, South Carolina, Florida, Maine, and New York. The company develops residential and commercial land development projects and other unimproved land, as well as projects in various stages of development, and retail and office operating properties.

Further Reading: What are catch-up contributions?

Receive News & Ratings for HomeFed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HomeFed and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Elastic  Rating Lowered to Sell at Zacks Investment Research
Elastic Rating Lowered to Sell at Zacks Investment Research
Diplomat Pharmacy  Stock Rating Lowered by Zacks Investment Research
Diplomat Pharmacy Stock Rating Lowered by Zacks Investment Research
Dicerna Pharmaceuticals  Rating Lowered to Sell at Zacks Investment Research
Dicerna Pharmaceuticals Rating Lowered to Sell at Zacks Investment Research
Eastgroup Properties  Rating Lowered to Hold at Zacks Investment Research
Eastgroup Properties Rating Lowered to Hold at Zacks Investment Research
Zacks Investment Research Upgrades NOW  to “Buy”
Zacks Investment Research Upgrades NOW to “Buy”
Zacks Investment Research Downgrades Endologix  to Hold
Zacks Investment Research Downgrades Endologix to Hold


© 2006-2019 Ticker Report